Evidence map›Paper›PMID 42316399›Full record

ArticleCancer medicine2026

Prognostic Value of Next-Generation Flow Cytometry Versus Dual-Tracer PET/CT for Minimal Residual Disease Assessment in Multiple Myeloma.

Runfeng Zhang, Wenjia Zhu, Lili Cheng, Jianhua Du, Fujing Zhang, Qiao Yang, Huijuan Wang, Yun Leng, Miao Chen, Li Huo and 1 more

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Runfeng ZhangDepartment of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China.ORCID https://orcid.org/0000-0003-0206-318X
Wenjia ZhuDepartment of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China.
Lili ChengDepartment of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China.ORCID https://orcid.org/0009-0007-0247-6829
Jianhua DuDepartment of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China.
Fujing ZhangDepartment of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China.
Qiao YangDepartment of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China.
Huijuan WangDepartment of Hematology, Beijing Chao-Yang Hospital, Beijing, China.
Yun LengDepartment of Hematology, Beijing Chao-Yang Hospital, Beijing, China.
Miao ChenDepartment of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China.
Li HuoDepartment of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China.
Junling ZhuangDepartment of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China.

Funding

CAMS Innovation Fund for Medical Sciences 2024-I2M-C&T-B-017National High Level Hospital Clinical Research 2025-PUMCH-C-040
6 · The paper itself

Abstract

To evaluate the comparative prognostic utility of next-generation flow cytometry (NGF) and dual-tracer PET/CT in measuring minimal residual disease (MRD), this prospective real-world study enrolled 118 newly diagnosed multiple myeloma (NDMM) patients. Patients underwent post-treatment assessment using NGF (sensitivity 10

Indexed as

Flow CytometryMultiple MyelomaNeoplasm, ResidualPositron Emission Tomography Computed TomographyAgedFemaleFluorodeoxyglucose F18HumansMalePrognosisProspective StudiesRadiopharmaceuticalsFluorodeoxyglucose F18Radiopharmaceuticalsminimal residual diseasemultiple myelomanext‐generation flow cytometrypositron emission computed tomographyprognosis

Identifiers

PMID42316399
PMCPMC13279452

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.